ReportGem ReportGem

U.S. COMPANY FILING

NORTHROP GRUMMAN CORP /DE/ — Form 10-Q filed 2026-07-21

Filed: 2026-07-21Company: NORTHROP GRUMMAN CORP /DE/Ticker: NOCExchange: NYSEForm: 10-QReport period: 2026-06-30SEC accession: 0001133421-26-000034Event: earningsMateriality: 85

Filing text preview

Northrop Grumman's Q2 2026 sales rose 5% to $10.876 billion, but operating income fell 23% to $1.096 billion due to prior-year divestiture gain and lower FAS/CAS adjustment. Net earnings decreased 7% to $1.094 billion, with diluted EPS of $7.68. For H1, sales grew 5% and net earnings rose 19%. B-21 program recorded a loss provision, while Sentinel program added $7.6 billion to backlog. Quarterly dividend increased 7% to $2.47 per share.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-21Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-20Nocera Files 8-K Disclosing Material Agreement and Management Changes2026-08-20Sinocell: SCTB10 injection obtains clinical trial approval2026-08-19Sinocell: Subsidiary SCTA02A Injection Gets Clinical Trial Approval2026-08-19Sinocell: Subsidiary SCTB10 Gets Clinical Trial Approval for Hemophilia A2026-08-198-K2026-07-21 · 8-K